| « Previous | Back to contents | Next » |
Test cases: Clinical trials in China
HOME > PAST ISSUE > COVER STORY [Premium content]September 2007
For pharma firms looking to test their products on a blank canvas, China has a large number of "naïve" patients that have not been exposed to other treatments.
There is little doubt that cost was the key factor when foreign drug companies first shifted their clinical trials to China.
"This is a very active area with a lot of companies going into it, especially for pre-clinical and discovery work. A lot can be done in these areas in China - you get a lot of bang for the buck," said Dr Zhu Shen, head of business development at US pharma company Immusol who formerly worked as a consultant to MNCs in China.
According to Excel China, ...
log in to continue reading...
 |
| « Previous | Back to contents | Next » |
To receive the best China business news that the market has to offer,
subscribe to the China Economic Review.
subscribe to the China Economic Review.